1. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. (February 2022) Authors: Danese, Silvio; Colombel, Jean-Frederic; Lukas, Milan; Gisbert, Javier P; D'Haens, Geert; Hayee, Bu'hussain; Panaccione, Remo; Kim, Hyun-Soo; Reinisch, Walter; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Tang, Meina Tao; Schreiber, Stefan; Aboo, Nazimuddin; ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Issue 5 (May 2023) Authors: Menzies-Gow, Andrew; Wechsler, Michael E; Brightling, Christopher E; Korn, Stephanie; Corren, Jonathan; Israel, Elliot; Chupp, Geoffrey; Bednarczyk, Artur; Ponnarambil, Sandhia; Caveney, Scott; Almqvist, Gun; Gołąbek, Monika; Simonsson, Linda; Lawson, Kaitlyn; Bowen, Karin; Colice, Gene; Hetzel, ... Journal: Lancet Issue: Volume 11:Issue 5(2023) Page Start: 425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗